Finoriq research workspace
X4 Pharmaceuticals, Inc (XFOR) SEC Filings & Filing Highlights
X4 Pharmaceuticals, Inc offers XOLREMDI, an orally small-molecule selective antagonist of. Review XFOR SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
- Company
- X4 Pharmaceuticals, Inc (XFOR)
- Ticker
- XFOR
- Market Cap
- $346.6M
- Latest Price
- $3.675
- Industry
- Biotech & Pharma
X4 Pharmaceuticals, Inc (XFOR) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for X4 Pharmaceuticals, Inc (XFOR).
| Event | Form | Date |
|---|---|---|
| X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Di...X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors | 8-K7.01 | 2026-07-01 |
| On June 30, 2026, of X4 Pharmaceuticals, Inc. (the “Company”) appointed Kelly Gold as a Class I...On June 30, 2026, of X4 Pharmaceuticals, Inc. (the “Company”) appointed Kelly Gold as a Class II director of the Company, effective as of J... | 8-K5.02 | 2026-07-01 |
| Election of the three Class III director nominees to serve until the 2029 Annual Meeting of Sto...The final results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting are set forth below. Th... | 8-K5.07 | 2026-05-12 |
| At the Annual Meeting, the Company’s stockholders approved the Company’s Second Amended and Res...At the Annual Meeting, the Company’s stockholders approved the Company’s Second Amended and Restated 2017 Equity Incentive Plan (as so amen... | 8-K5.02 | 2026-05-12 |
| X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateX4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update | 8-K2.02 | 2025-11-05 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.